Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,593.96
(
-0.46%
)
US TECH 100
23,566.40
(
-0.96%
)
Dow Jones
45,922.83
(
-0.65%
)
Brent Oil
105.75
(
-0.78%
)
Bitcoin
69,470.00
(
-2.49%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: cjgaddy post# 52690

Saturday, 09/22/2007 3:54:08 PM

Saturday, September 22, 2007 3:54:08 PM

Post# of 257259
HCV: Most Likely to Succeed (IMHO)

In descending order of likelihood of success:

1. Telaprevir (VRTX/JNJ in phase-2).

2. The enhanced interferons: Albuferon (NVS/HGSI in phase-3) and Locteron (OctoPlus/Biolex in phase-2). I’m excluding Maxy-alpha from MAXY, which is now on hold, and ifn-lambda from ZGEN, which is an altogether different animal.

3. The “other” protease inhibitors: Boceprevir (SGP in phase-2) and ITMN-191 (Roche/ITMN in phase-1).

4. Various early-stage compounds from GILD (alone), GILD/ACHN, Roche/VRUS, Medivir/Tibotec, and IDIX.

JMHO, FWIW

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now